Director Benefit Risk
Sanofi R&D epidemiology & BR
Bill has more than 20 years of experience in Drug Research and Development with Sanofi companies. Bill received his Doctorate in Cell and Structural Biology from the University of Illinois at Urbana-Champaign after completing his thesis on “The Molecular Basis of Mammalian Circadian Rhythms”. After postdoctoral research, Bill joined the CNS Discovery group at Aventis and subsequently transitioned through successive stages of the Drug R&D process with positions in Lead Identification and Optimization, Candidate Selection, Translational Medicine, Phase 3 Clinical Trials and new Drug Submission activities. In those roles, Bill lead teams and contributed to projects on Circadian Rhythm Disorders, Diabetes, Cognitive Impairment, Biology of Aging, Alzheimer’s and other Dementias, Depression, Narcolepsy, Excessive Daytime Sleepiness, Schizophrenia and Multiple Sclerosis. As a Clinical Scientist, he performed Benefit Risk Triage during multiple FDA Advisory Committees for new drug submissions and subsequently took a position as medical Benefit Risk Expert contributing across the Sanofi therapeutic portfolio. Bill is also a member of the Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) Working Group for creating a standard Structured Benefit-Risk template for vaccines.